New Alliances at a Glance
To achieve our goals of bringing safe and effective medicines to patients in need, as well as achieving long-term growth, Daiichi Sankyo partners with a variety of organizations to focus on progressing promising products that complement our in-house portfolio.
Our strategy involves in-licensing new products and product candidates, acquiring companies that will drive our portfolio in key therapeutic areas, as well as partnering on specific aspects of research, development and/or commercialization.
Our decades-long history of effective collaboration exemplifies our ability to license products in and out of Daiichi Sankyo, develop and maintain valuable partnerships, and successfully complete mergers and acquisitions.
Here is a snapshot of our activity:
A clinical trial collaboration to evaluate the combination of patritumab deruxtecan (U3-1402), a HER3 directed DXd antibody drug conjugate (ADC), and TAGRISSO (osimertinib), an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), in patients with EGFR-mutated advanced or metastatic non-small cell lung cancer (NSCLC).
A global development and commercialization collaboration for Daiichi Sankyo’s DS-1062, a TROP2 directed DXd antibody drug conjugate (ADC), currently in phase 1 clinical development for non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC).
A multi-year, multi-study research collaboration for the development of two of Daiichi Sankyo’s lead DXd antibody drug conjugates (ADCs): DS-1062, a TROP2 directed DXd ADC, in patients with advanced non-small cell lung cancer (NSCLC), and patritumab deruxtecan (U3-1402), a HER3 directed DXd ADC, in patients with metastatic breast cancer.
Merck & Co., Inc.
A clinical trial collaboration agreement with MSD, a subsidiary of Merck & Co., Inc., to evaluate the combination of DS-1062, a TROP2 directed DXd antibody drug conjugate (ADC), and KEYTRUDA® (pembrolizumab) in patients with previously-treated advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations.
Sarah Cannon Research Institute
A strategic oncology development collaboration bringing together Daiichi Sankyo's expertise in developing novel cancer agents with Sarah Cannon's leadership in designing and optimizing clinical trials to expand treatment options for patients with cancer. Currently progressing two investigational antibody drug conjugates (ADC): DS 6157, a GPR20 directed ADC, in patients with advanced gastrointestinal stromal tumor (GIST) and DS-7300, a B7-H3 directed ADC, in patients with metastatic solid cancers.
A strategic coalition to bring promising cancer therapies to patients as safely, effectively and efficiently as possible. Syneos Health will provide both strategic and operational solutions for the three lead Daiichi Sankyo DXd antibody drug conjugates.
A global development and commercialization collaboration for Daiichi Sankyo’s trastuzumab deruxtecan* (DS-8201)
A collaboration agreement for the development of a new HER2 low companion diagnostic test.
Merck & Co., Inc.
A clinical trial collaboration agreement to evaluate the combination of Daiichi Sankyo's trastuzumab deruxtecan* (DS-8201) and KEYTRUDA® (pembrolizumab) in HER2 expressing advanced/metastatic breast and HER2 expressing or HER2 mutant non-small cell lung cancers (NSCLC)
Merck KGaA & Pfizer, Inc.
A clinical trial collaboration agreement to evaluate the combination of Daiichi Sankyo's trastuzumab deruxtecan* (DS-8201) in combination with the checkpoint inhibitor avelumab and/or an investigational Merck KGaA DNA damage response (DDR) inhibitor, in patients with HER2 expressing or mutated solid tumors
Sarah Cannon Research Institute
A strategic oncology development collaboration bringing together Daiichi Sankyo's expertise in developing novel cancer agents with Sarah Cannon's leadership in designing and optimizing clinical trials to expand treatment options for patients
An exclusive worldwide licensing agreement to develop an antibody drug conjugate (ADC) by combining Daiichi Sankyo’s proprietary ADC technology with Glycotope’s investigational tumor-associated TA-MUC1 antibody gatipotuzumab (formerly PankoMab-GEX®) building on a previous 2017 option agreement
A research agreement providing Daiichi Sankyo with exclusive access to DarwinHealth’s proprietary novel cancer target database in order to identify potential new targets for cancer drug development
A licensing agreement to acquire licenses to Zymeworks’ Azymetric™ and EFECT™ technologies to develop two additional bispecific antibodies building on previous 2016 cross-licensing and collaboration agreement
Merck & Co., Inc.
A clinical trial collaboration agreement to evaluate the combination of Daiichi Sankyo’s trastuzumab deruxtecan* (DS-8201) and KEYTRUDA® (pembrolizumab) in HER2 expressing advanced/metastatic breast and HER2 expressing or HER2 mutant non-small cell lung cancers (NSCLC).
A preclinical research collaboration with Puma Biotechnology, Inc. and Memorial Sloan Kettering Cancer Center in HER2-mutated cancer or HER2-positive solid tumors.
MD Anderson Cancer Center
A strategic oncology development collaboration with MD Anderson focused on accelerating the development of novel therapies for acute myeloid leukemia (AML) by studying Daiichi Sankyo’s AML pipeline in novel combination regimens.
A clinical trial collaboration agreement to evaluate Opdivo® (nivolumab) and Daiichi Sankyo's trastuzumab deruxtecan* (DS-8201) in HER2-expressing breast and bladder cancers
Max Planck Innovation GmbH and Lead Discovery Center GmbH
An agreement between Daiichi Sankyo, Max Planck Innovation and the Lead Discovery Center providing Daiichi Sankyo with the option to receive the exclusive rights to a new lead compound for the treatment of cancer to be discovered and developed at the Lead Discovery Center
Heptares Therapeutics, the wholly owned subsidiary of Sosei Group Corporation
A drug discovery and licensing agreement with Heptares Therapeutics, part of the Sosei Group, that is focused on a single G protein-coupled receptor (GPCR) that plays a crucial role in relieving pain
A strategic partnership with Kite Pharma, a subsidiary of Gilead Sciences, Inc., for the exclusive rights of development, manufacturing and commercialization in Japan of Kite’s cellular cancer therapy axicabtagene ciloleucel (KTE-C19)
An exclusive agreement to commercialize nine biosimilars in Japan, including several biosimilars in late stage development, including biosimilars of adalimumab, bevacizumab and trastuzumab
An agreement with Celixir for an exclusive license in Japan to develop and market Heartcel™, an immune-modulatory progenitor (iMP) cell therapeutic agent for ischemic heart failure currently in development
A strategic collaboration with AgonOx, Inc. to develop an undisclosed immuno-oncology target
Inspirion Delivery Sciences
A collaboration to commercialize two abuse-deterrent opioid medications, MorphaBond™ ER and RoxyBond™, both of which feature a unique, patent-protected abuse-deterrent technology
A co-commercialization agreement for Movantik®, a medication indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain
Sanford-Burnham Medical Research Institute
A comprehensive alliance to develop first-in-class therapeutics for the treatment of cardiovascular-metabolic diseases. The collaboration is built on an open-innovation model to bridge the gap between target discovery and pre-clinical drug development.
Virtici, LLC and Celdara Medical, LLC
A collaboration to jointly investigate novel therapeutic candidates and thereby further strengthen the Daiichi Sankyo developmental pipeline across multiple therapeutic areas
University of California, San Francisco
A drug discovery collaboration focused on developing novel therapeutics and molecular diagnostics for multiple neurodegenerative diseases
Note: This is not a complete list of Daiichi Sankyo alliances
*fam-trastuzumab deruxtecan-nxki in the U.S. only